Viktor Rossiev

Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study

Heinz Gisslinger, Christoph Klade, Pencho Georgiev et al. · The Lancet Haematology · 2020 · 347 citations

Pharmacy, Hematology, Pharmacotherapy +5

Effect of FCGR2A and FCGR3A variants on CLL outcome

David Dornan, Olivia Spleiss, Ru-Fang Yeh et al. · Blood · 2010 · 60 citations · Full text

Life Sciences, Immunology, Oncology +16

Final Results from PROUD-PV a Randomized Controlled Phase 3 Trial Comparing Ropeginterferon Alfa-2b to Hydroxyurea in Polycythemia Vera Patients

Heinz Gisslinger, Christoph Klade, Pencho Georgiev et al. · Blood · 2016 · 28 citations

Pharmacy, Pharmacology, Pharmacotherapy +3

Evidence for Superior Efficacy and Disease Modification after Three Years of Prospective Randomized Controlled Treatment of Polycythemia Vera Patients with Ropeginterferon Alfa-2b Vs. HU/BAT

Heinz Gisslinger, Christoph Klade, Pencho Georgiev et al. · Blood · 2018 · 20 citations

Pharmacy, Hematology, Pharmacotherapy +6

PTK2 expression and immunochemotherapy outcome in chronic lymphocytic leukemia

Ru‐Fang Yeh, Guillemette Duchâteau-Nguyen, Giuseppe Palermo et al. · Blood · 2014 · 19 citations · Full text

Life Sciences, Hematology, Oncology +14